| # | Company | Location | Employees | Total Funding | Last Round | Last Funded |
|---|---|---|---|---|---|---|
| 1 |
Aktis Oncology
Aktis Oncology is a biotechnology company that designs and develops novel class …
|
Boston | 51 - 100 | $331.0M | Series B | 2024-09-30 |
| 2 |
Freenome
Freenome is a biotechnology company developing blood tests for early cancer dete…
|
South San Francisco | 251 - 500 | $1.5B | Corporate Round | 2025-11-17 |
| 3 |
Erasca
Erasca is a developer of oncology drugs intended to provide precision oncology o…
|
San Diego | 101 - 250 | $854.0M | Post Ipo Equity | 2026-01-21 |
| 4 |
BlossomHill Therapeutics
BlossomHill Therapeutics is a biopharmaceutical company focusing on oncology and…
|
San Diego | 11 - 50 | $257.0M | Series B | 2025-12-10 |
| 5 |
Cartography Biosciences
Cartography is an oncology company that develops cancer immunotherapies that tar…
|
South San Francisco | 11 - 50 | $124.0M | Series B | 2025-10-02 |
| 6 |
Replicate Bioscience
Replicate Bioscience develops self-replicating RNA therapeutics and vaccines del…
|
San Diego | 11 - 50 | $53.0M | Grant | 2026-01-08 |
| 7 |
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating…
|
Cambridge | 101 - 250 | $823.4M | Post Ipo Equity | 2026-03-27 |
| 8 |
Massive Bio
Massive Bio is an AI powered oncology platform that connects patients to clinica…
|
New York | 101 - 250 | $23.8M | Series B | 2022-06-02 |
| 9 |
ErVimmune
ErVimmune develops cancer vaccines and T cell therapies targeting cold tumors us…
|
Lyon | 11 - 50 | $27.7M | Series A | 2026-01-21 |
| 10 |
Roche
Roche is a pharmaceutical and diagnostics company that offers medicines and diag…
|
Basel | c 10001 max | $7.8B | Post Ipo Equity | 2021-08-04 |
| 11 |
Transcode Therapeutics
TransCode Therapeutics is an RNA oncology company that develops and commercializ…
|
Newton | 11 - 50 | $73.0M | Post Ipo Debt | 2026-04-07 |
| 12 |
Odyssey Therapeutics
Odyssey Therapeutics creates precision immunomodulators and oncology medicines f…
|
Cambridge | 51 - 100 | $700.0M | Series D | 2025-09-10 |
| 13 |
Avenzo Therapeutics
Avenzo Therapeutics specializes in the development of oncology therapies for can…
|
San Diego | 11 - 50 | $841.9M | Series B | 2025-09-04 |
| 14 |
Thyme Care
Thyme Care is a healthcare company that provides oncology care management servic…
|
Nashville | 101 - 250 | $274.0M | Series D | 2025-09-25 |
| 15 |
MAIA Biotechnology
MAIA Biotechnology is a clinical-stage biopharmaceutical company developing canc…
|
Chicago | 1 - 10 | $75.7M | Post Ipo Equity | 2026-03-02 |
| 16 |
ConcertAI
ConcertAI is an AI-powered SaaS data company that develops medical research tool…
|
Cambridge | 1K - 5K | $300.0M | Series C | 2022-03-29 |
| 17 |
Mission Bio
Mission Bio develops only single-cell multi-omics platform integrating genotype …
|
San Francisco | 101 - 250 | $150.9M | Series Unknown | 2025-08-05 |
| 18 |
The Oncology Institute of Hope and Innovation
The Oncology Institute of Hope and Innovation is providing professional support …
|
Downey | 501 - 1K | $291.5M | Post Ipo Equity | 2025-03-24 |
| 19 |
Xilio Therapeutics
Xilio Therapeutics is a biotechnology company that develops tumor-activated immu…
|
Waltham | 51 - 100 | $370.1M | Post Ipo Equity | 2026-02-11 |
| 20 |
CG Oncology
CG Oncology is a clinical-stage biopharmaceutical company focused on the develop…
|
Irvine | 101 - 250 | $555.6M | Post Ipo Equity | 2024-12-12 |
| 21 |
Triomics
Triomics is a generative AI-powered platform that matches patients to clinical t…
|
San Francisco | 101 - 250 | $15.1M | Non Equity Assistance | 2024-07-02 |
| 22 |
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule t…
|
Boulder | 51 - 100 | $460.0M | Post Ipo Equity | 2025-06-13 |
| 23 |
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing i…
|
Cambridge | 51 - 100 | $245.5M | Post Ipo Equity | 2024-04-09 |
| 24 |
Reimagine Care
Reimagine Care is a health care company that provides technology-enabled service…
|
Nashville | 11 - 50 | $27.4M | Series Unknown | 2025-12-16 |
| 25 |
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is a center dedicated to carrying out adult and ped…
|
Boston | 5K - 10K | $88.1M | Grant | 2025-11-24 |
| 26 |
Leo Cancer Care
Leo Cancer Care constantly seeking to optimise and improve.
|
Harley | 11 - 50 | $65.3M | Series Unknown | 2025-09-24 |
| 27 |
Opna Bio
Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery …
|
Epalinges | 11 - 50 | $38.0M | Series A | 2022-11-21 |
| 28 |
Outcomes4Me
Outcomes4Me develops direct-to-patient AI-driven platform designed to assist can…
|
Boston | 11 - 50 | $37.7M | Series A | 2025-05-29 |
| 29 |
SAGA Diagnostics
Liquid biopsy testing specialists. Ultrasensitive cancer diagnosis and monitorin…
|
Lund | 11 - 50 | $18.0M | Series A | 2021-06-29 |
| 30 |
Adcytherix
Adcytherix is a biopharmaceutical firm that specializes in the development of ne…
|
Marseille | 11 - 50 | $155.1M | Series A | 2025-10-16 |
| 31 |
Pyxis Oncology
Pyxis Oncology is a biotechnology firm that develops antibody therapeutics inten…
|
Boston | 11 - 50 | $224.0M | Post Ipo Equity | 2024-02-27 |
| 32 |
Harbour Biomed
Harbour BioMed is a clinical stage biopharmaceutical company developing innovati…
|
Shanghai | 101 - 250 | $417.8M | Post Ipo Equity | 2025-03-21 |
| 33 |
Leadoptik
Leadoptik is a deep-tech company specializing in building a miniature imaging pl…
|
San Jose | 11 - 50 | $11.5M | Series Unknown | 2025-09-02 |
| 34 |
Silexion Therapeutics
Silexion Therapeutics is a biotechnology company that provides research and deve…
|
Illinois City | 11 - 50 | $12.8M | Post Ipo Equity | 2025-09-11 |
| 35 |
xCures
xCures is a SaaS platform that aggregates, organizes and structures EMRs providi…
|
Oakland | 11 - 50 | $13.0M | Convertible Note | 2023-12-01 |
| 36 |
Neok Bio
Neok Bio is a biotech startup that focuses on bispecific ADCs in cancer therapy.
|
Palo Alto | 1 - 10 | $75.0M | Series A | 2026-03-30 |
| 37 |
Guardant Health
Guardant Health is a precision oncology company that uses blood tests, data sets…
|
Redwood City | 1K - 5K | $2.5B | Post Ipo Equity | 2025-11-05 |
| 38 |
T-CURX
T-CURX develops personalized T cell therapies for cancer, leveraging a proprieta…
|
W├╝rzburg | 1 - 10 | $20.0M | Series A | 2025-12-17 |
| 39 |
Tevogen Bio
Tevogen Bio develops immunotherapy solutions for treating cancer, neurological c…
|
Warren | 11 - 50 | $67.0M | Post Ipo Equity | 2025-08-19 |
| 40 |
Adlai Nortye
Adlai Nortye is a clinical-stage biopharmaceutical company that deveops cancer t…
|
Hangzhou | 51 - 100 | $433.0M | Post Ipo Equity | 2026-04-16 |
| 41 |
Valar Labs
Valar Labs offers assistance services for cancer treatment through Artificial In…
|
Palo Alto | 1 - 10 | $26.0M | Series A | 2024-05-30 |
| 42 |
LIfT BioSciences
LIfT Biosciences is a biotech company that develops allogeneic cell therapies us…
|
London | 11 - 50 | $38.4M | Grant | 2025-07-29 |
| 43 |
Kivu Bioscience
Kivu Bioscience is a biotechnology company that focuses on developing next-gener…
|
San Francisco | 11 - 50 | $92.0M | Series A | 2024-10-28 |
| 44 |
Crossbow Therapeutics
Crossbow Therapeutics is a biotech company developing a new type of cancer treat…
|
Cambridge | 11 - 50 | $187.2M | Series B | 2026-03-18 |
| 45 |
DEM BioPharma
DEM BioPharma is an immuno-oncology company that is working to eradicate cancer …
|
Cambridge | 11 - 50 | $70.0M | Series A | 2022-06-23 |
| 46 |
AdvanCell
AdvanCell is a clinical-stage radiopharmaceutical company developing targeted al…
|
Sydney | 11 - 50 | $137.9M | Grant | 2025-04-13 |
| 47 |
Tyra Biosciences
Tyra Biosciences is a biotechnology company targeting new pathways of acquired r…
|
Carlsbad | 11 - 50 | $356.0M | Post Ipo Equity | 2024-02-02 |
| 48 |
Cancer Research UK
Cancer Research UK pioneers life-saving research to bring forward the day when a…
|
London | 1K - 5K | $5.2M | Grant | 2024-11-01 |
| 49 |
Stand Up To Cancer
Stand Up To Cancer is engaged in funded cancer research for cancer treatment.
|
Los Angeles | 51 - 100 | $4.0M | Grant | 2021-04-19 |
| 50 |
Diakonos Oncology
Diakonos Oncology biotech firm developing dendritic cell vaccines targeting diff…
|
Houston | 11 - 50 | $38.4M | Grant | 2025-12-10 |